SCHEMBL4579443

SCHEMBL4579443

C#Cc1cncc2ccc(C(=O)O)nc12

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CCNC P24863 2/20 0.45
CDK8 P49336 2/20 0.45
KDM4E B2RXH2 6/20 0.44
KMT2A Q03164 2/20 0.44
MGAM O43451 1/20 0.40
TDP1 Q9NUW8 2/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
ACMSD Q8TDX5 1/20 0.38
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
MMP2 P08253 2/20 0.36
P4HA1 P13674 1/20 0.34
MIF P14174 1/20 0.34
P4HTM Q9NXG6 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4580571 0.80 KDM4E (0.42) CCNCCDK8KDM4EKMT2AMGAM
SCHEMBL9286173 0.80 KDM4E (0.60) KDM4EKMT2AMGAMTDP1ALOX15
SCHEMBL13313431 0.77 KDM4E (0.61) CCNCCDK8KDM4EKMT2AMGAM
SCHEMBL29850571 0.76 CCNC (0.47) CCNCCDK8KDM4EKMT2AMGAM
SCHEMBL578828 0.76 CCNC (0.47) CCNCCDK8KDM4EKMT2AMGAM
SCHEMBL6641803 0.76 CCNC (0.47) CCNCCDK8KDM4EKMT2AMGAM
SCHEMBL12114712 0.76 CCNC (0.50) CCNCCDK8KDM4EKMT2AMGAM
SCHEMBL4580096 0.75 MMP2 (0.42) CCNCCDK8KDM4EKMT2AMGAM
Hydrochloric Acid SCHEMBL4580182 0.75 CCNC (0.46) CCNCCDK8KDM4EKMT2AMGAM
SCHEMBL4579857 0.72 CCNC (0.64) CCNCCDK8KDM4EKMT2AMGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives SERENEX, INC. 2008-02-07 US claimed
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US claimed
EP-1773834-A2 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES Serenex, Inc. (US) 2007-04-18 EP claimed
WO-2006017672-A2 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES SERENEX INC. (US) 2006-02-16 WO claimed
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives SERENEX, INC. 2006-02-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives CCNA1, FOXM1, CCNA2 CCNC 289/4885CDK8 516/4885KDM4E 3744/4885
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives CCNA1, FOXM1, CCNA2 CCNC 289/4885CDK8 516/4885KDM4E 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.